Selective progesterone receptor modulators (SPRMs) are a new class of compounds
developed to target the progesterone receptor (PR) with a mix of agonist and antagonist …

Uterine fibroids (UFs) are the most important benign neoplastic threat to women's health
worldwide, with a prevalence of up to 80% in premenopausal women, and can cause heavy …

BACKGROUND Despite intense research, it remains intriguing why hormonal therapies in
general and progestins in particular sometimes fail in endometriosis. OBJECTIVE AND …

Uterine fibroids are the most common benign neoplasm of the female reproductive tract in
reproductive age women. Their prevalence is age dependent and can be detected in up to …

Introduction Uterine fibroids are the most common benign gynecological tumors affecting
women of reproductive ages. Although surgery is the definitive treatment choice, several …

Background Leiomyomas (fibroids), the most common benign solid tumours in females,
originate from the myometrium and are associated with poor quality of life for patients. The …

There appear to be very few data on the exact mechanisms of a selective progesterone
receptor modulator action in myomas. The aim of the study was to assess the effects of …

Objective Vilaprisan is a highly potent selective progesterone receptor modulator shown to
reduce heavy menstrual bleeding, induce amenorrhea, and diminish uterine fibroid volume …

Objective To assess the efficacy of vilaprisan compared with placebo in the management of
the symptoms of uterine fibroids (UF), with a secondary objective to provide a descriptive …

Background: Vilaprisan (VPR) is a new orally available selective progesterone receptor
modulator (SPRM), with anti-proliferative activity against uterine fibroids (UFs). It definitively …